SET Announcements | Bangkok Lab and Cosmetic

EN TH

Home
Who We Are
Who We Are

A comprehensive healthcare solutions group, comprising generic and new generic drugs, herbal medicines, animal medicines, cosmetics, food supplements, and other health products. The Company’s operation covers the complete value chain of healthcare business from research and development, to manufacturing, to sales and marketing and distribution.

Read more
What We Do
What We Do

The company manufactures and sells a comprehensive range of health products via two types of business models: B2B and B2C.
Investors
Investors
Sustainability
Sustainability

The Company has laid out sustainability management policies and goals in three dimensions, encompassing the environment, society, and good corporate governance with transparency and verification to create trusted solutions for lifelong well-being (good health and good quality of life) for everyone.”
News
News
Careers
Careers

Grow With Us - Experience a workplace where diversity thrives, creating a strong and sustainable future for the nation.
- Why work with BLC
- Application Form
Contact Us

Notification of the Resolutions of the 2025 Annual General Meeting of Shareholders

Notification of the Resolutions of the 2025 Annual General Meeting of Shareholders

Submitting Questions before the 2025 Annual General Meeting of Shareholders

The Amendment of the Scope, Authority, Duties and Responsibilities of the Audit Committee

Determination of Invitation Letter to the 2025 Annual General Meeting of Shareholders

25 February 2025

Determination of the Date and Agenda for the 2025 Annual General Meeting of Shareholders and Dividend Payment (Revised)

24 February 2025

Determination of the Date and Agenda for the 2025 Annual General Meeting of Shareholders and Dividend Payment

24 February 2025

Management Discussion and Analysis Yearly Ending 31 Dec 2024

24 February 2025

Financial Performance Yearly (F45) (Audited)

24 February 2025

Financial Statement Yearly 2024 (Audited)

10 January 2025

Report of the Utilization of Capital Increase from Initial Public Offering (IPO)

11 November 2024

Management Discussion and Analysis Quarter 3 Ending 30 Sep 2024

1
2
3
4
5